Traws Pharma, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
TRAW Nasdaq 2830 www.trawspharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Traws Pharma, Inc.

Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program - Jun 22nd, 2026 5:00 am
SpaceX initiated, Salesforce upgraded: Wall Street's top analyst calls - Jun 18th, 2026 7:35 am
Traws Pharma Shares Slide After UK Regulator Postpones Influenza Study - Jun 15th, 2026 4:26 am
Why Did TRAW Stock Slump 28% After Hours? - Jun 12th, 2026 6:07 pm
Traws Pharma Provides Regulatory Update on Influenza Program - Jun 12th, 2026 3:30 pm
Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks - May 27th, 2026 6:45 am
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results - May 15th, 2026 5:00 am
Sector Update: Healthcare Stocks Lower Late Afternoon - May 8th, 2026 1:58 pm
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections - May 8th, 2026 5:30 am
Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Apr 20th, 2026 7:55 am
Traws Pharma, Inc. Q4 2025 Earnings Call Summary - Apr 16th, 2026 6:30 am
Traws Pharma Inc (TRAW) Q4 2025 Earnings Call Highlights: A Turnaround Year with Significant ... - Apr 16th, 2026 1:01 am
Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights - Apr 15th, 2026 2:01 pm
Traws Pharma Announces Up to $60 Million Private Placement Financing - Apr 15th, 2026 6:15 am
hVIVO, Connecting Excellence, ACG Metals, Kodal Minerals, Ariana Resources, Sunda Energy - Apr 14th, 2026 2:17 am
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza - Feb 19th, 2026 5:30 am
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza - Jan 26th, 2026 6:30 am
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients - Jan 13th, 2026 5:00 am
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors - Dec 22nd, 2025 6:01 am
Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients - Dec 17th, 2025 4:00 am